The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin

Thrombosis Research

Volumn 125, Issue 6, 2010, Pages

  Abderrazek, Fatma ^a   Chakroun, Tahar ^b   Addad, Faouzi ^a   Dridi, Zohra ^a   Gerotziafas, Grigoris ^c   Gamra, Habib ^a   Hassine, Mohsen ^a   Elalamy, Ismail ^c  

^a FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^b FARHAT HACHED HOSPITAL   (Tunisia)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; COLLAGEN; GLYCOPROTEIN IIIA; GLYCOPROTEIN IIIA PIA1; GLYCOPROTEIN IIIA PIA2; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; BETA3 INTEGRIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; THROMBOCYTE AGGREGATION; TUNISIA; BLOOD CLOTTING PARAMETERS; DRUG EFFECTS; GENETICS; MIDDLE AGED; THROMBOCYTE;

AGED; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; FEMALE; GENOTYPE; HUMANS; INTEGRIN BETA3; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, GENETIC; TUNISIA;

EID: 77952550106     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.01.011     Document Type: Article

References (19)

1. Antithrombolic trialist collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324 (2002) 71-86
2. Gasparyan A.Y., Watson T., and Lip G.Y. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 51 (2008) 1829-1843
3. Feher G., Feher A., Pusch G., Lupkovics G., Szapary L., and Papp E. The genetics of antiplatelet drug resistance. Clin Genet 75 (2009) 1-18
4. Shattil S.J., Kashiwagi H., and Pampori N. integrin signialing:the platelet paradigm. Blood 91 (1998) 2645-2657
5. Newman P.J., Derbes R.S., and Aster R.H. The human platelet alloantigen, PllA1 and PlA2, are associated with a Leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 83 (1989) 1778-1781
6. Feng D., lindpaintner K., Larson M.G., Rao V.S., O'Donnell C.J., Lipinska I., et al. Increased platelet aggregability associated with platelet GPIIa PlA2 polymorphism: The Framingham Offspring Study. Arterioscler Thromb Vasc Biol 19 (1999) 1142-1147
7. Goodman T., Ferro A., and Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 66 (2008) 222-232
8. Lev E.I., Patel R.T., Guthikonda S., Lopez D., Bray P.F., and Kleiman N.S. Genetic polymorphisms of the platelet receptors P2Y (12), P2Y (1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 119 (2007) 355-360
9. Addad F., Chakroun T., Abderazek F., Ben-Farhat M., Hamdi S., Dridi Z., et al. Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease. J Thromb Thrombolysis 19 (2009)
10. Cook GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-clermont PJ. PLA2 polymorphism and efficacity of aspirin. Lancet 1998;351:1253.
11. Macchi L, Christiaens L, Brabant S, et al. Resistance In vitro to low-dose Aspirin is associated with platelet PLA1 (GP IIIa) polymorphism but not with C 807T (GPIa/IIa) and C-ST Kozak (GPIbα) polymorphisms. J Am Coll cardiol 2003;42:5-9.
12. Michelson A.D., Furman M.I., Goldschmidt-clermont P.J., Mascelli M.A., Hendrix C., Coleman L., et al. Platelet GPIIIa Pl (A) polymorphisms display different sensitivities to agonists. Circulation 101 (2000) 1013-1018
13. Gonzalez-Conejero R., Rivera J., Corral J., Acuna C., Guerrero J.A., and Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?. Stroke 36 (2005) 276-280
14. Naran N.H., Chetty N., and Crowther N.J. The prevalence of the glycoprotein IIIa PlA1/PlA2 polymorphism in three south African ethnic groups and its effect on platelet function. Thromb Res 123 (2008) 316-323
15. Cooke G.E., Liu-Strattom Y., Ferketich A.K., Moeschberger M.L., Frid D.J., Magorien R.D., et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, Clopidogrel, or their combination. J Am Coll Cardiol 47 (2006) 541-546
16. Papp E., Havasi V., Bene J., Komlosi K., Czopf L., Magyar E., et al. Glycoprotein IIIa gene (PlA) polymorphism and aspirin resistance: is there any correlation?. Ann Pharmacother 39 (2005) 1013-1018
17. Pamukcu B., Oflaz H., and Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J 149 (2005) 675-680
18. Chakroun T., Addad F., Abderazek F., Ben-Farhat M., Hamdi S., Gamra H., et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. Thromb Res 121 (2007) 413-418
19. Lordkipanidzé M., Pharand C., Schampaert E., Turgeon J., Palisaitis D.A., and Diodati J.G. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28 (2007) 1702-1708